This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Parker Waichman LLP
The U.S. Food and Drug Administration (FDA) is evaluating Merck’s Januvia, Bristol-Myers Squibb’s Byetta and other diabetes medications due to a potential link to pancreatic cancer. The agency said that it found evidence of pre-cancerous cell changes in pancreatic tissue samples; Parker Waichman LLP offers expert commentary on these developments.
New York, New York (PRWEB) March 15, 2013
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is warning about the potential risk of pancreatitis and pancreatic cancer allegedly associated with the use of Januvia, Byetta and other similar diabetes medications. According to a Bloomberg report published on March 14, 2013 the U.S. Food and Drug Administration (FDA) is investigating the drugs due to an allegedly potential link to pancreatic cancer.
“Research suggests that these medications can lead to pancreatitis, which is a risk factor for pancreatic cancer,” says Parker Waichman LLP. The national personal injury law firm offers free legal advice to patients taking allegedly defective medical devices and drugs, including Januvia and Byetta.
On Thursday the FDA said it found inflammation and evidence of pre-cancerous cell changes in pancreatic tissue samples taken from patients taking the drugs. The diabetes drugs being investigated are known as incretin mimetics; they include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto).
Previous research has linked drugs such as Januvia and Byetta to pancreatitis and pancreatic cancer. In 2011, the journal Gastroenterology published a study showing that Januvia and Byetta users may have a 6-fold increased risk of pancreatitis as well as an increased risk for pancreatic cancer. The researchers also found a significantly higher rate of thyroid cancer among patients taking Byetta. Last month, JAMA Internal Medicine published a study showing that patients who take Byetta or Januvia may be twice as likely to develop pancreatitis.
Diabetes drugs such as Januvia and Byetta have raised concerns about damage to the pancreas since 2007, when the U.S. Food and Drug Administration (FDA) said that it received a high number of reports of pancreatitis linked to the use of Byetta. In 2009, the agency issued a similar warning for Januvia.
Parker Waichman LLP continues to offer free legal consultations to victims who suffered alleged injuries from Januvia, Byetta or Victoza, including pancreatitis, pancreatic cancer and thyroid cancer. If you or a loved one were diagnosed with pancreatitis, pancreatic cancer or thyroid after taking Januvia, Byetta or Victoza, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebbyettajanuviacancer/032013/prweb10534371.htm